SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) January 6, 2000
E. I. du Pont de Nemours and Company
(Exact Name of Registrant as Specified in Its Charter)
Delaware 1-815 51-0014090
(State or Other Jurisdiction (Commission (I.R.S Employer
of Incorporation) File Number) Identification No.)
1007 Market Street
Wilmington, Delaware 19898
(Address of principal executive offices)
Registrant's telephone number, including area code: (302) 774-1000
1
<PAGE>
Item 5. Other Events
------------
In connection with Debt and/or Equity Securities that may be offered
on a delayed or continuous basis under Registration Statements on Form S-3
(No. 33-53327, No. 33-61339, No. 33-60069 and No. 333-86363), the registrant
hereby files the following press release.
Contact: Susan Gaffney
(302) 774-2698
[email protected]
LANDGRAF NAMED CEO OF DUPONT PHARMACEUTICAL COMPANY
---------------------------------------------------
WILMINGTON, Del., Jan. 6 -- DuPont today announced that Kurt M.
Landgraf, executive vice president and chief operating officer, will become
chief executive officer of The DuPont Pharmaceutical Company, a wholly owned
independent subsidiary of DuPont. Landgraf will also assume chairmanship of a
newly created Pharmaceutical Advisory Board made up of DuPont executives and
external pharmaceutical industry executives who will add expertise to the
company's objective of creating a rich pipeline with specific therapeutic
focus.
"This move enhances our ability to grow our pharmaceuticals business,"
said Charles O. Holliday, Jr., DuPont chairman and CEO. "We examined numerous
potential large ventures, but we concluded that they did not increase share-
holder value. Continuing to build an integrated system of highly focused
marketing and research alliances is the best path toward meeting both our
strategic and shareholder value objectives."
Holliday noted, "I expect that the multiple alliances strategy will
create for us a larger and more profitable business unit, and I have great
confidence that Kurt's 30 years of experience in the industry he knows so well
make him the ideal choice to lead our effort."
Landgraf said, "Over the past six months, DuPont Pharmaceuticals has
acquired CombiChem and ImaRx and has formed significant research collabo-
rations with Pharmasset and Duke University. I am confident in our ability to
create growth by capitalizing on these and future alliances, as well as our
market-leading positions in SustivaTM efavirenz and "Coumadin" warfarin sodium
and the financial gains from our partnership with Merck on "Cozaar" losartan
potassium."
2
<PAGE>
The DuPont Pharmaceuticals company is a wholly owned subsidiary of
DuPont with specific franchise leadership in cardiovascular/thrombosis,
virology and neurology therapeutics.
The DuPont is a science company, delivering science-based solutions
that make a difference in people's lives in food and nutrition; health care;
apparel; home and construction; electronics; and transportation. Founded in
1802, the company operates in 65 countries and has 97,000 employees.
Forward-Looking Statements: This news release contains forward-looking state-
ments based on management's current expectations, estimates and projections.
All statements that address expectations or projections about the future,
including statements about the company's strategy for growth, product develop-
ment, market position, expected expenditures and financial results are
forward-looking statements. Some of the forward-looking statements may be
identified by words like "expects," "anticipates," "plans," "intends,"
"projects," "indicates," and similar expressions. These statements are not
guarantees of future performance and involve a number of risks, uncertainties
and assumptions. Many factors, including those discussed more fully elsewhere
in this release and in DuPont's filings with the Securities and Exchange
Commission, particularly its latest annual report on Form 10-K, as well as
others, could cause results to differ materially from those stated. These
factors include, but are not limited to changes in the laws, regulations,
policies and economic conditions of countries in which the company does
business; competitive pressures; successful integration of structural changes,
including acquisitions, divestitures and alliances; failure of the company or
related third parties to become Year 2000 capable; research and development of
new products, including regulatory approval and market acceptance, seasonality
of sales in its Agriculture & Nutrition segment.
###
1/6/00
3
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
E. I. DU PONT DE NEMOURS AND COMPANY
(Registrant)
/s/ D. B. Smith
------------------------------------
D. B. Smith
Assistant Controller
January 6, 2000
4
